| | A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malign...A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors - Full ... |
|
|
Conditions: Malignancy; Non-hodgkin Lymphoma; Multiple Myeloma; Breast Cancer; Ovarian Cancer; Soft Tissue Sarcoma; Squamous Cell Carcinoma; Head and Neck Cancer; DLBCL; Mantle Cell Lymphoma; Follicular Lymphoma; Leiomyosarcoma; Pancreatic Cancer; Sarcoma; CLLIntervention: Drug: CYT-0851Sponsor: Cyteir Therapeutics, Inc.Not yet recruiting
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,00306932607174,alsfakia@gmail.com,